Each week our research team reviews the latest insider filings to see where the people closest to these businesses are quietly putting capital to work.
For the week of March 9-13, we narrowed the field to nine names that stood out based on purchase size, buyer role, accumulation patterns, and whether the buying lined up with other signals we track.
As we worked through the list and ran the names through our proprietary Alpha Signal Score, one stock quickly separated itself from the rest. Several of our key signals were lining up at the same time.
I’ll come back to that company in just a moment. First, here are the most notable insider purchases from last week…
Most Notable Insider Purchases From Last Week
| Ticker | Company | Buyer | Value | What Stood Out |
|---|---|---|---|---|
| CPNG | Coupang | Neil Mehta | $136.5M | Huge multi-day insider-linked accumulation, though via stock appreciation rights |
| SNDA | Sonida Senior Living | Michael Simanovsky | $100M | Enormous one-day cash bet on a turnaround |
| ALKT | Alkami Technology | General Atlantic | $50.6M | Major growth investor accumulating over several days |
| AHCO | AdaptHealth | Richard Cashin | $19.9M | Consistent three-day accumulation in a defensive healthcare name |
| FOX | Fox Corp | Lachlan Murdoch | $10.6M | Murdoch family increasing exposure via stock rights |
| TGLS | Tecnoglass | Energy Holding | $13.2M | Major holder adding systematically |
| KRRO | Korro Bio | Multiple insiders | $18.4M | Clustered insider participation in a beaten-down biotech turnaround |
| SONO | Sonos | Coliseum Capital | $13.0M | Activist-style accumulation in a consumer turnaround |
| STAA | STAAR Surgical | Broadwood Partners | $12.3M | Accelerating hedge fund buying over three days |
If needed, swipe or scroll sideways to view the full table.
How to Use This List
Insider buying can offer useful clues about where company leadership or major holders believe value exists.
But it’s rarely the whole story.
Some insider purchases are more meaningful than others. A cash buy usually matters more than a mechanical conversion. A cluster of buys often matters more than a single token purchase. And in some cases — especially in biotech — participation in a financing can be just as important as open-market buying, because it tells you who is willing to fund the next stage of the story.
That’s why insider activity is best viewed as a starting point for research — not a standalone trading signal.
In our experience, the most compelling setups tend to emerge when insider buying starts to line up with other signals — things like institutional sponsorship, analyst sentiment, technical structure, and upcoming catalysts.
That’s when the picture starts to get much more interesting.
One Name Stood Out
After reviewing last week’s filings, we took the most interesting candidates and ran them through our proprietary Alpha Signal Score — a framework we use to evaluate multiple signals across a stock.
A few names scored well, but one checked nearly every box.
That stock is Korro Bio (KRRO). And if there’s such a thing as a “dream” biotech turnaround setup, this may be close.
Here’s why it stood out.
1) The insider signal was clustered — and it came at an important moment
In biotech, timing is everything. When insiders are willing to commit capital after a major washout — not before — it can signal that the people closest to the story believe the next phase may look very different from the last one. And in KRRO’s case, the timing was hard to ignore.
The stock had already been through its collapse and sentiment had already been wrecked…
… then fresh money showed up. On March 10, insiders bought roughly $18 million worth of shares.
2) This wasn’t just insider interest — institutions showed up too
One reason KRRO rose to the top of our list is that this wasn’t happening in a vacuum.
The company also secured a fresh $85 million financing, led by Venrock Healthcare Capital Partners, with participation from a number of institutional investors.
In small-cap biotech, that kind of sponsorship matters. It tells you the market isn’t just speculating on hope — sophisticated capital is willing to fund the next chapter.
That’s an important distinction. A lot of broken biotech stories stay broken because they run out of time. KRRO just bought itself more of it.
3) Wall Street is starting to flip
This may be one of the most interesting parts of the setup.
Last November, KRRO looked dead.
The company’s earlier AATD program disappointed, sentiment collapsed, and the market treated the stock like another failed biotech experiment.
But over the last several weeks, that tone has started to change.
Analysts have been coming back to the name as the new story has taken shape. Recent targets in the low-$20s — and in some cases higher — suggest the Street is no longer treating KRRO like a dead story.
It’s starting to treat it like a recovery story.
| Firm | Latest View | Price Target | Upside vs. $12.43 | What It Suggests |
|---|---|---|---|---|
| Raymond James | Outperform | $23 | +85% | Fresh March validation that the Street is warming up to the turnaround. |
| Cantor Fitzgerald | Overweight | $22 | +77% | Maintained bullishness and raised its target as the recovery story improved. |
| Oppenheimer | Outperform | $22 | +77% | Another sign that the post-crash narrative has changed meaningfully. |
| Clear Street | Buy | $18 | +45% | A more conservative target — but still well above current levels. |
| Piper Sandler | Overweight | $30 | +141% | The high-end bull case if the turnaround continues to prove itself. |
Upside calculations are based on KRRO trading at $12.43. If needed, swipe or scroll sideways to view the full table.
4) The science story improved — and that’s what really matters
Plenty of biotech stocks bounce after a crash, but very few deserve to.
What makes KRRO interesting is that this doesn’t look like a random rebound. It looks like a company that may have found a more credible path forward.
The company has outlined a new path built around KRRO-121 and its GalNAc AATD program, with the story now anchored by a clearer development roadmap and a much more focused recovery narrative.
That’s a very different setup from the one investors were looking at just a few months ago.
And in biotech, credible pivots matter.
A failed first act doesn’t always kill the story — not if the platform still has life, the new direction makes more sense, and the catalyst calendar — which I’ll go over next — gives investors a reason to re-engage.
KRRO checks those boxes.
5) The catalyst path is real
Part of what makes KRRO so interesting is that there are multiple milestones ahead that could keep the story in front of investors. And, if execution holds, the potential for the market to keep re-rating the story before the next major clinical milestones arrive.
That’s the kind of setup we like to see in speculative biotech: a story with multiple shots at proving itself over the next several quarters.
| Timing | Milestone | Why It Matters |
|---|---|---|
| Q2 2026 | GalNAc AATD development candidate nomination | Would further validate the company’s post-pivot platform and show progress beyond the November washout. |
| H2 2026 | KRRO-121 regulatory filing | A key step toward moving the lead program into the clinic. |
| Late 2026 | Potential Phase 1 initiation for KRRO-121 | This would shift the story from preclinical promise to human testing. |
| H1 2027 | Potential early Phase 1 read-through | If early human data are encouraging, that’s where the turnaround story could start to get re-priced more aggressively. |
If needed, swipe or scroll sideways to view the full table.
6) Even the lack of options activity tells you something
Interestingly, KRRO did not show the kind of unusual options activity we saw in names like CPNG.
Normally, that might be a knock. Here, I don’t think it is.
KRRO is still a smaller biotech name with a thinner options market, which means the absence of big options flow isn’t especially surprising.
In names like this, the better tell is often not the options tape — it’s the combination of insider participation, institutional sponsorship, analyst momentum, and a live catalyst calendar.
And that’s exactly what we have here.
The Takeaway
There were other interesting names on this week’s list, but KRRO has something they don’t: a cluster of signals showing up within days of each other…
| Date | Signal | What Happened | Why It Matters |
|---|---|---|---|
| Mar 9 | Institutional Sponsorship | Korro secured an $85 million PIPE financing led by Venrock Healthcare Capital Partners. | Fresh capital gave the company more runway and signaled outside conviction in the turnaround story. |
| Mar 10 | Insider Cluster | Nine directors and insiders participated in roughly $18 million of buying on the same day. | Coordinated insider participation is rare — and often points to unusually high internal conviction. |
| Mar 12 | Visible Path of Catalysts | Management reiterated key milestones, including a Q2 2026 AATD candidate nomination and an H2 2026 regulatory filing for KRRO-121. | The story now has a visible path of catalysts instead of a vague “maybe someday” timeline. |
| Mar 13 | Analyst Validation | Raymond James upgraded KRRO to Outperform with a $23 target. | Wall Street sentiment is beginning to flip — exactly the kind of shift we like to see in a turnaround. |
| Now | Asymmetric Setup | The stock is still trading near $12.43, well below where bullish analyst targets now sit. | That leaves room for a meaningful re-rating if the turnaround continues to gain credibility. |
If needed, swipe or scroll sideways to view the full table.
This is the kind of stock that already had its washout and lost the crowd. Now it has fresh capital, clustered insider participation, improving Wall Street sentiment, a more credible scientific narrative, and a catalyst path that could keep investors focused on the name for the rest of 2026.
That’s a rare combination. And it’s exactly the kind of setup our Alpha Signal Score is designed to catch.
Individually, any one of these signals would be interesting. But when insiders, institutions, analysts, and catalysts all begin lining up in the same direction, the picture becomes much more compelling.
That’s why KRRO stood out as the most exciting name from this week’s insider-buy list.
Of course, this is still biotech, which means it’s volatile… and position sizing matters.
But that’s also the opportunity.
Because by the time a biotech turnaround feels comfortable, the biggest upside is usually already gone.
Good trading,
Greg Patrick
P.S. KRRO is exactly the kind of stock our Alpha Signal Score is built to surface — not because one signal looks good, but because multiple signals begin lining up at the same time. And when that starts happening in a beaten-down biotech, things can get interesting fast. Trade accordingly.